Orforglipron

FDA-approved product existsMetabolic ResearchWeight & metabolic
5.8

Worth trying, BioHarmony verdict

BioHarmony score 5.8 out of 10

Orforglipron (Foundayo) is the first FDA-approved non-peptide oral GLP-1 pill, cleared for obesity in April 2026. It cut body weight about 11.2 percent at 72 weeks in the ATTAIN-1 Phase 3 trial, less than the injectables but with once-daily oral convenience and no food or water restrictions.

Read full report

What is Orforglipron?

Orforglipron, sold as Foundayo, is the first non-peptide GLP-1 receptor agonist you can swallow as a daily pill, and that one fact is the whole reason it matters. Every other GLP-1 drug that works well, semaglutide and tirzepatide, is a peptide that stomach enzymes would shred, so it has to be injected or, in oral semaglutide's case, wrapped in a fussy absorption trick. Orforglipron is a small molecule. Enzymes leave it alone, it absorbs at roughly 79 percent, and you take it any time of day with or without food.

From the BioHarmony report, reviewed Sep 8, 2026.

Saved on this device only.

Safety watch-outs

  • Severe, persistent abdominal pain, possibly radiating to the back (possible pancreatitis): stop and seek care immediately.
  • A lump or swelling in the neck, hoarseness, or trouble swallowing (thyroid warning): stop and consult a clinician.
  • Personal or family history of medullary thyroid cancer or MEN2: do not use.
  • Repeated vomiting or signs of dehydration during titration: pause and reassess the dose with a clinician.

Full risk profile in the BioHarmony report.

Dosing as published

Source-reported figures only. This page does not calculate a personal dose.

Approved labelFOUNDAYO prescribing information for approved chronic weight-management indications
PopulationAdults covered by the approved FOUNDAYO indication
DoseStart at 0.8 mg once daily. After at least 30 days increase to 2.5 mg, then after at least 30 more days increase to 5.5 mg. The label permits subsequent 30-day steps to 9 mg, 14.5 mg, and a maximum of 17.2 mg once daily based on response and tolerability. With a strong CYP3A4 inhibitor the label caps the dosage at 9 mg once daily. Avoid strong CYP3A4 inhibitors that also inhibit OATP1B when taking FOUNDAYO. If 7 or more consecutive doses are missed, reinitiate dosage escalation at a lower dosage.
RouteOral tablet, swallowed whole
FrequencyOnce daily, with or without food
DurationLong-term use within the approved indication; each escalation interval is at least 30 days
PreparationReady-to-use tablet; no reconstitution. Do not break, crush, or chew.
Source: Dosage and Administration sections 2.1-2.3; Dosage Forms and Strengths section 3; Drug Interactions section 7.1

More reported protocols

Members

Members can compare additional reported doses, schedules, and preparation notes.

Educator coverage (2)

Attributed viewpoints, separate from primary research.

Trust & sourcing

  1. Last revieweddone
  2. Next reviewupcoming
US approvalFDA-approved product exists
CompoundingApproved product exists; compounded copies are not FDA approved

Lilly reports that FDA approved orforglipron as Foundayo in April 2026 for chronic weight management in certain adults.

Primary sources

The Ultimate Peptides Guide

Spot stronger candidates, weak evidence, and seller red flags before you buy.

Free. Includes evidence and regulatory updates. Unsubscribe anytime.